Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-guided early discontinuation of empirical antifungal therapy in ICU patients with suspected invasive Candida infection
2017-003793-13Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Apr 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluconazole, caspofungin and micafungin in invasive candidiasis and candidiasis (2 arms), sponsored by CHU de Lille. Primary endpoint: Early discontinuation of empirical antifungal therapy. Started Apr 2018; status: completed.
02
Drugs
fluconazolecaspofunginmicafungin
03
Conditions
invasive candidiasiscandidiasis
Beyond the preview
Go deeper on 2017-003793-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003793-13.